BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Rizzo G, Pugliese D, Armuzzi A, Coco C. Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery? World J Gastroenterol 2014; 20(17): 4839-4845 [PMID: 24803795 DOI: 10.3748/wjg.v20.i17.4839]
URL: https://www.wjgnet.com/1007-9327/full/v20/i17/4839.htm
Number Citing Articles
1
Jørgen Jahnsen. Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsTherapeutic Advances in Gastroenterology 2016; 9(3): 322 doi: 10.1177/1756283X16636764
2
Kasumi Hishinuma, Rintaro Moroi, Daisuke Okamoto, Yusuke Shimoyama, Masatake Kuroha, Hisashi Shiga, Yoichi Kakuta, Yoshitaka Kinouchi, Atsushi Masamune. Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility LociInflammatory Intestinal Diseases 2021; 6(3): 154 doi: 10.1159/000518371
3
Quinton M. Hatch, Rubina Ratnaparkhi, Alison Althans, Michael Keating, Ruel Neupane, Madhuri Nishtala, Eric K. Johnson, Scott R. Steele. Is Modern Medical Management Changing Ultimate Patient Outcomes in Inflammatory Bowel Disease?Journal of Gastrointestinal Surgery 2016; 20(11): 1867 doi: 10.1007/s11605-016-3275-z
4
Sara Kolehmainen, Anna Lepistö, Martti Färkkilä. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016Scandinavian Journal of Gastroenterology 2019; 54(6): 707 doi: 10.1080/00365521.2019.1620326
5
Daniel J Wong, Eve M Roth, Joseph D Feuerstein, Vitaliy Y Poylin. Surgery in the age of biologicsGastroenterology Report 2019; 7(2): 77 doi: 10.1093/gastro/goz004
6
George Khoudari, Emad Mansoor, Benjamin Click, Motasem Alkhayyat, Mohannad Abou Saleh, Preetika Sinh, Jeffry Katz, Gregory S. Cooper, Miguel Regueiro. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort StudyClinical Gastroenterology and Hepatology 2022; 20(5): e974 doi: 10.1016/j.cgh.2020.10.008
7
Marjorie C. Argollo, Paulo Gustavo Kotze, Antonino Spinelli, Tarcia N.F. Gomes, Silvio Danese. The impact of biologics in surgical outcomes in ulcerative colitisBest Practice & Research Clinical Gastroenterology 2018; : 79 doi: 10.1016/j.bpg.2018.05.014
8
Anthony Mark Dalzell, Muhammad Eyad Ba’Ath. Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countriesPaediatrics and International Child Health 2019; 39(1): 48 doi: 10.1080/20469047.2019.1575056
9
Laura Wilhelmina Byrne, Damian McKay. Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic reviewThe Surgeon 2021; 19(5): e153 doi: 10.1016/j.surge.2020.09.001
10
Pablo Olivera, Antonino Spinelli, Corinne Gower-Rousseau, Silvio Danese, Laurent Peyrin-Biroulet. Surgical rates in the era of biological therapyCurrent Opinion in Gastroenterology 2017; 33(4): 246 doi: 10.1097/MOG.0000000000000361
11
R. Ruppert. Infliximab bei Colitis ulcerosacoloproctology 2014; 36(6): 489 doi: 10.1007/s00053-014-0489-y
12
Eleonora Scaioli, Alessandro Sartini, Elisa Liverani, Richard John Digby, Giampaolo Ugolini, Giancarlo Rosati, Gilberto Poggioli, Davide Festi, Franco Bazzoli, Andrea Belluzzi. Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch–Anal Anastomosis for Ulcerative ColitisDigestive Diseases and Sciences 2017; 62(4): 1016 doi: 10.1007/s10620-017-4454-9
13
Ahmed Al‑Dwairi, Mohammad Alqudah, Othman Al‑Shboul, Mahmoud Alfaqih, Dana Alomari. Metformin exerts anti‑inflammatory effects on mouse colon smooth muscle cells in�vitroExperimental and Therapeutic Medicine 2018;  doi: 10.3892/etm.2018.6222
14
Manuel Ferrer Márquez, Álvaro Hernández Martínez, Ángel Reina Duarte, Rafael Rosado Cobián. Estado actual del tratamiento de la colitis fulminanteCirugía Española 2015; 93(5): 276 doi: 10.1016/j.ciresp.2014.09.016
15
Yong Jiang, Zhi‐Guang Zhang, Feng‐Xiang Qi, Ying Zhang, Tao Han. Comparison of maintenance effect of probiotics and aminosalicylates on ulcerative colitis: A meta‐analysis of randomized controlled trialsChronic Diseases and Translational Medicine 2016; 2(1): 34 doi: 10.1016/j.cdtm.2016.07.002
16
Kay-Martin Johnsen, Rasmus Goll, Vegard Hansen, Trine Olsen, Renathe Rismo, Richard Heitmann, Mona D. Gundersen, Jan M. Kvamme, Eyvind J. Paulssen, Hege Kileng, Knut Johnsen, Jon Florholmen. Repeated intensified infliximab induction – results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithmEuropean Journal of Gastroenterology & Hepatology 2017; 29(1): 98 doi: 10.1097/MEG.0000000000000753
17
Chen Diling, Yang Xin, Zheng Chaoqun, Yang Jian, Tang Xiaocui, Chen Jun, Shuai Ou, Xie Yizhen. Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiotaOncotarget 2017; 8(49): 85838 doi: 10.18632/oncotarget.20689
18
Manuel Ferrer Márquez, Álvaro Hernández Martínez, Ángel Reina Duarte, Rafael Rosado Cobián. Current Status of the Treatment of Fulminant ColitisCirugía Española (English Edition) 2015; 93(5): 276 doi: 10.1016/j.cireng.2014.09.009